Calliditas Therapeutics AB (publ) provided revenue guidance for the year ending December 31, 2024. For the year, the company expects continued revenue growth: total net sales are estimated to be USD 150-180 million for the year ending December 31, 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
122.6 SEK | +6.33% | +6.98% | -5.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.90% | 571M | |
+8.36% | 72.5B | |
+13.69% | 9.11B | |
-11.75% | 5.07B | |
+59.61% | 5.01B | |
+2.62% | 3.85B | |
-17.54% | 2.46B | |
+21.35% | 2.44B | |
-27.82% | 2.26B | |
+25.13% | 2.27B |
- Stock Market
- Equities
- CALTX Stock
- News Calliditas Therapeutics AB
- Calliditas Therapeutics AB Provides Revenue Guidance for the Year Ending December 31, 2024